Michalina A. Montano

Michalina A. Montano

Auto-generated profile, based on publicly available information

Michalina A. Montano

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2018 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
MMMichalina A. Montaño
Michalina A. Montaño
JDJulia C. Dombrowski
Julia C. Dombrowski
SDSayan Dasgupta
Sayan Dasgupta
MGMatthew R. Golden
Matthew R. Golden
ADAnn Duerr
Ann Duerr
CKChristine M. Khosropour
Christine M. Khosropour

26 June 2019 in AIDS Care
Verified
Journal Article
Open access
ALAugust Longino
August Longino
MMMichalina A. Montano
Michalina A. Montano
HSHugo Sanchez
Hugo Sanchez
ABAngela Bayer
Angela Bayer
JSJorge Sanchez
Jorge Sanchez
YMYamilé Molina
Yamilé Molina
In Perú, men who have sex with men (MSM) and transgender women (TW) suffer rates of HIV 50 times greater than the general population. MSM or TW sex workers (SWs) are at especially high risk. Daily oral pre-exposure prophylaxis (PrEP) effectively prevents HIV infection if patients adhere to a daily or on-demand regimen. Necessary levels of adoption and adherence require data-driven intervention strategies for these marginalized groups. We conducted qualitative content analysis of data obtained from focus groups (FGs) with MSM and TW SWs. Both groups expressed strong skepticism about the motives behind international drug trials, and the safety of participating in them. Important differences between MSM and TW groups’ beliefs about trustworthy information as well as community and public institutions also emerged. MSM SWs were less trusting of information from other MSM SWs, and preferred to receive information from institutional medical sources, while TGW SWs preferred to receive information from other TGW SWs. Successful strategies to encourage PrEP uptake and adherence must address the distrust patients feel towards international and institutional actors by providing patients with tailored, reliable information from local and community sources that they trust.

1 September 2019 in AIDS
Verified
Journal Article
Closed access
MMMichalina A. Montaño
Michalina A. Montaño
JDJulia C. Dombrowski
Julia C. Dombrowski
SDSayan Dasgupta
Sayan Dasgupta
MGMatthew R. Golden
Matthew R. Golden
LMLisa E. Manhart
Lisa E. Manhart
CKChristine M. Khosropour
Christine M. Khosropour
Objective: The aim of this study was to determine whether MSM using preexposure prophylaxis (PrEP) are at a higher risk of bacterial sexually transmitted infections (STIs) than MSM not using PrEP. Design: Secondary analysis of longitudinal STI data obtained from MSM attending an STD Clinic in Seattle, Washington, USA, October 2011–September 2017. Methods: We identified patients obtaining PrEP through the STD Clinic, and used propensity score matching to select a historical group of similar patients not using PrEP for comparison. We linked patient data with STI surveillance data to compare the incidence of chlamydia, gonorrhoea and early syphilis, and time to first symptomatic STI among PrEP users and nonusers. Results: Three hundred and sixty-five PrEP users who picked up prescriptions and returned for follow-up and 730 propensity score matched nonusers were included in the analysis. Adjusted incidence rate ratios (aIRRs) for chlamydia, gonorrhoea and early syphilis were 3.2 [95% confidence interval (95% CI): 1.9–5.3], 2.8 (95% CI: 1.7–4.6) and 2.9 (95% CI: 1.5 – 5.6), respectively, comparing PrEP users to nonusers. Time to first symptomatic STI was shorter among PrEP users (120 days, 95% CI: 77 – 171) than among nonusers (185 days, 95% CI: 163–256). Conclusion: Among MSM on PrEP, we observed a higher incidence of STIs and faster time to first symptomatic STI than MSM not using PrEP. PrEP may be a contributing factor in increasing STI rates among MSM.

8 October 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
MMMichalina Montaño
Michalina Montaño
ASAdrienne E Shapiro
Adrienne E Shapiro
BWBridget M Whitney
Bridget M Whitney
LBLaura Bamford
Laura Bamford
GBGreer Burkholder
Greer Burkholder
RIRachel A Bender Ignacio
Rachel A Bender Ignacio
Introduction: Since its global reemergence in 2022, monkeypox (mpox) has demonstrated increased incidence and severity among people with human immunodeficiency virus (HIV [PWH]). Predictors of mpox diagnosis, vaccination, and outcomes among PWH are limited. Methods: We included PWH with primary care visits after 1 January 2022 at 9 US sites participating in the Centers for AIDS Research Network of Integrated Clinic Systems Network. We identified mpox diagnosed between 1 June 2022 and 31 May 2023, through a combination of polymerase chain reaction result, diagnosis code, and/or tecovirimat receipt. We examined validated clinical diagnoses, laboratory results, vaccine data, and patient reported outcomes. We evaluated relative risks (RR) of mpox diagnosis, hospitalization, tecovirimat treatment, and vaccine receipt. Findings: Among 19 777 PWH in care, 413 mpox cases (all male sex at birth) occurred (2.2 cases/100 person-years). Age <40 years, geographic region, Hispanic/Latine ethnicity, lack of antiretroviral therapy, detectable HIV viral load, and recent bacterial sexually transmitted infection predicted mpox diagnosis. PWH with CD4 200–349 cells/mm3 were most likely to be hospitalized (adjusted RR, 3.20; 95% confidence interval: 1.44–7.09) compared to CD4 ≥500, but half as likely as those with CD4 <200 to receive tecovirimat. Overall, smallpox/mpox vaccine effectiveness of ≥1 vaccine was 71% (adjusted RR, 0.29; 95% confidence interval: .14–.47) at preventing mpox, and 86% or better with CD4 ≥350 or HIV viral suppression. Non-Hispanic Black PWH were less likely to be vaccinated than other racial/ethnic identities. Interpretation: PWH not on antiretroviral therapy or with unsuppressed HIV were more likely to be diagnosed with, and hospitalized for, mpox. Mpox/smallpox vaccine effectiveness was high, inclusive of those with low CD4 count and HIV viremia.

2 February 2021 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
MMMichalina A Montaño
Michalina A Montaño
MCMaganizo B Chagomerana
Maganizo B Chagomerana
MBMargaret Z. Borok
Margaret Z. Borok
MPMatthew Painschab
Matthew Painschab
TUThomas S Uldrick
Thomas S Uldrick
RIRachel A Bender Ignacio
Rachel A Bender Ignacio

9 February 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MMMichalina A. Montaño
Michalina A. Montaño
MBMeagan J. Bemer
Meagan J. Bemer
KHKate B. Heller
Kate B. Heller
AMAllison Meisner
Allison Meisner
ZMZarna Marfatia
Zarna Marfatia
Paul DrainPaul Drain
Paul Drain
This study assesses and compares the performance of different swab types and specimen collection sites for SARS-CoV-2 testing, to reference standard real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and viral culture. Symptomatic adults with COVID-19 who visited routine COVID-19 testing sites used spun polyester and FLOQSwabs to self-collect specimens from the anterior nares and tongue. We evaluated the self-collected specimen from anterior nares and tongue swabs for the nucleocapsid (N) or spike (S) antigen of SARS-CoV-2 by RT-PCR and then compared these results with results from RT-PCR and viral cultures from nurse-collected nasopharyngeal swabs. Diagnostic sensitivity was highest for RT-PCR testing conducted using specimens from the anterior nares collected on FLOQSwabs (84%; 95% CI 68-94%) and spun polyester swabs (82%; 95% CI 66-92%), compared to RT-PCR tests conducted using specimens from nasopharyngeal swabs. Relative to viral culture from nasopharyngeal swabs, diagnostic sensitivities were higher for RT-PCR and antigen testing of anterior nares swabs (91-100%) than that of tongue swabs (18-81%). Antigen testing of anterior nares swabs had higher sensitivities against viral culture (91%) than against nasopharyngeal RT-PCR (38-70%). All investigational tests had high specificity compared with nasopharyngeal RT-PCR. Spun polyester swabs are equally effective as FLOQSwabs for anterior nasal RT-PCR testing. We found that anterior nares specimens were more sensitive than tongue swab specimens or antigen testing for detecting SARS-CoV-2 by RT-PCR. Thus, self-collected anterior nares specimens may represent an alternative method for diagnostic SARS-CoV-2 testing in some settings.